NovaQuest
NovaQuest Capital Management is a private equity firm based in Raleigh, North Carolina, established in 2000. The firm specializes in structured finance investments primarily within the healthcare and biopharmaceutical sectors, focusing on late-stage clinical and commercialized products. NovaQuest collaborates with global companies on strategic product programs, offering customized investment solutions that diverge from traditional biopharmaceutical deal-making. The firm also invests in select private equity and other securities, maintaining a commitment to enhancing the value of product portfolios. With over $1 billion invested in the healthcare industry, the experienced team at NovaQuest has developed a consistent investment strategy that adapts to the evolving needs of healthcare companies and their investors. The firm's product and co-investment funds target various sectors, including pharmaceuticals, biotechnology, life sciences, and healthcare technology systems.
Applied LifeSciences & Systems is a bio-systems company focused on improving animal health and productivity in the poultry, livestock, and aquaculture industries. ALS-S is developing a solution that revolutionizes current vaccination methods. Our technology will detect, target, and deliver vaccines to each and every chick, ensuring effective vaccination. This one-of-a-kind accuracy and consistency in the vaccination process boosts the natural immune response to diseases, improves overall flock health, and provides for a cleaner, healthier chick.
Private Equity Round in 2021
Aceragen is a developer of therapeutic treatments intended for rare and ultra-rare diseases.
Private Equity Round in 2018
Clinical Ink, Inc. specializes in eSource and patient engagement solutions designed to enhance the efficiency of clinical research for sites, sponsors, contract research organizations (CROs), and patients. The company offers a range of products, including SureSource, an electronic source platform that facilitates the electronic capture of data and documents at clinical sites. Additionally, Clinical Ink provides Lunexis ePRO+, a technology that simplifies the implementation process and allows flexibility for patient participation. The CentrosHealth platform further engages patients through configurable applications that ensure they remain informed and compliant throughout clinical trials. Founded in 2006, Clinical Ink is headquartered in Horsham, Pennsylvania, with additional offices in North Carolina, Philadelphia, and Cambridge, Massachusetts. The company maintains a strategic alliance with CogState Limited.
Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.